JP2016534157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534157A5 JP2016534157A5 JP2016550681A JP2016550681A JP2016534157A5 JP 2016534157 A5 JP2016534157 A5 JP 2016534157A5 JP 2016550681 A JP2016550681 A JP 2016550681A JP 2016550681 A JP2016550681 A JP 2016550681A JP 2016534157 A5 JP2016534157 A5 JP 2016534157A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- lymphoma
- use according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 53
- 201000011510 cancer Diseases 0.000 claims 49
- 210000003719 b-lymphocyte Anatomy 0.000 claims 32
- 230000036210 malignancy Effects 0.000 claims 28
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 22
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 20
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 20
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 16
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 12
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 12
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 11
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 11
- 206010006187 Breast cancer Diseases 0.000 claims 10
- 208000026310 Breast neoplasm Diseases 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 206010025323 Lymphomas Diseases 0.000 claims 10
- 208000029742 colonic neoplasm Diseases 0.000 claims 10
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 8
- 229960001507 ibrutinib Drugs 0.000 claims 8
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 8
- 201000005787 hematologic cancer Diseases 0.000 claims 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 6
- 201000009777 distal biliary tract carcinoma Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 6
- 201000002528 pancreatic cancer Diseases 0.000 claims 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 6
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 230000002489 hematologic effect Effects 0.000 claims 5
- 229940124291 BTK inhibitor Drugs 0.000 claims 4
- 102100038078 CD276 antigen Human genes 0.000 claims 4
- 201000004085 CLL/SLL Diseases 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 4
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 4
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 4
- 102000017578 LAG3 Human genes 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 4
- 206010070308 Refractory cancer Diseases 0.000 claims 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 4
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000024312 invasive carcinoma Diseases 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 208000037819 metastatic cancer Diseases 0.000 claims 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- -1 CD86 Proteins 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- 101150051188 Adora2a gene Proteins 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100024263 CD160 antigen Human genes 0.000 claims 2
- 102100038077 CD226 antigen Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102100031351 Galectin-9 Human genes 0.000 claims 2
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 2
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 2
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 208000002163 Phyllodes Tumor Diseases 0.000 claims 2
- 206010071776 Phyllodes tumour Diseases 0.000 claims 2
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 206010038111 Recurrent cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 claims 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 201000005389 breast carcinoma in situ Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 208000022136 colorectal lymphoma Diseases 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000001079 digestive effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 2
- 208000030776 invasive breast carcinoma Diseases 0.000 claims 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000011059 lobular neoplasia Diseases 0.000 claims 2
- 108091005446 macrophage receptors Proteins 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895988P | 2013-10-25 | 2013-10-25 | |
| US61/895,988 | 2013-10-25 | ||
| US201361899764P | 2013-11-04 | 2013-11-04 | |
| US61/899,764 | 2013-11-04 | ||
| US201361911953P | 2013-12-04 | 2013-12-04 | |
| US61/911,953 | 2013-12-04 | ||
| US201461937392P | 2014-02-07 | 2014-02-07 | |
| US61/937,392 | 2014-02-07 | ||
| US201461968312P | 2014-03-20 | 2014-03-20 | |
| US61/968,312 | 2014-03-20 | ||
| US201462023705P | 2014-07-11 | 2014-07-11 | |
| US201462023742P | 2014-07-11 | 2014-07-11 | |
| US62/023,705 | 2014-07-11 | ||
| US62/023,742 | 2014-07-11 | ||
| PCT/US2014/062278 WO2015061752A1 (en) | 2013-10-25 | 2014-10-24 | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019064721A Division JP2019142890A (ja) | 2013-10-25 | 2019-03-28 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534157A JP2016534157A (ja) | 2016-11-04 |
| JP2016534157A5 true JP2016534157A5 (https=) | 2017-12-07 |
| JP6508785B2 JP6508785B2 (ja) | 2019-05-08 |
Family
ID=52993668
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550681A Expired - Fee Related JP6508785B2 (ja) | 2013-10-25 | 2014-10-24 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| JP2019064721A Ceased JP2019142890A (ja) | 2013-10-25 | 2019-03-28 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| JP2020210693A Pending JP2021063091A (ja) | 2013-10-25 | 2020-12-18 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019064721A Ceased JP2019142890A (ja) | 2013-10-25 | 2019-03-28 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| JP2020210693A Pending JP2021063091A (ja) | 2013-10-25 | 2020-12-18 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150118222A1 (https=) |
| EP (1) | EP3060251A4 (https=) |
| JP (3) | JP6508785B2 (https=) |
| KR (1) | KR20160066554A (https=) |
| CN (1) | CN105848680A (https=) |
| AU (2) | AU2014339816B2 (https=) |
| BR (1) | BR112016009200A8 (https=) |
| CA (1) | CA2927794A1 (https=) |
| EA (1) | EA201690746A1 (https=) |
| IL (1) | IL245042A0 (https=) |
| MX (1) | MX2016005283A (https=) |
| TW (2) | TWI617309B (https=) |
| WO (1) | WO2015061752A1 (https=) |
Families Citing this family (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10058621B2 (en) * | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| ES2660418T3 (es) | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
| CN103068830B (zh) | 2010-04-22 | 2016-06-29 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| DK2632927T3 (en) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| US9138436B2 (en) | 2011-07-13 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| DK2786996T3 (en) | 2011-11-29 | 2016-12-19 | Ono Pharmaceutical Co | Hydrochloride PURINONDERIVAT |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| JO3754B1 (ar) | 2012-06-04 | 2021-01-31 | Pharmacyclics Llc | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| EA201590855A1 (ru) | 2012-11-15 | 2015-11-30 | Фармасайкликс, Инк. | Соединения пирролопиримидина как ингибиторы киназ |
| HRP20170217T1 (hr) | 2013-04-25 | 2017-04-21 | Beigene, Ltd. | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze |
| CA2919996A1 (en) | 2013-08-02 | 2015-02-05 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
| US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| CA2925124A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2015095404A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| JP6528779B2 (ja) | 2014-03-25 | 2019-06-12 | 小野薬品工業株式会社 | びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤 |
| RS61273B1 (sr) | 2014-04-30 | 2021-01-29 | Fujifilm Corp | Lipozomska kompozicija i postupak za njeno dobijanje |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| US11186640B2 (en) * | 2014-07-31 | 2021-11-30 | The University Of Western Australia | Method for the identification of immunotherapy-drug combinations using a network approach |
| AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| SG11201700849XA (en) | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
| MA40596B1 (fr) * | 2014-08-11 | 2021-12-31 | Acerta Pharma Bv | Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2 |
| TW201618773A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| US20170239351A1 (en) * | 2014-08-11 | 2017-08-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor |
| WO2016128912A1 (en) * | 2015-02-12 | 2016-08-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| EP3267969A1 (en) * | 2015-03-09 | 2018-01-17 | King's College London | Combination therapy with rar alpha agonists for enhancing th1 response |
| GB2536650A (en) | 2015-03-24 | 2016-09-28 | Augmedics Ltd | Method and system for combining video-based and optic-based augmented reality in a near eye display |
| CN104878104B (zh) * | 2015-06-01 | 2018-05-04 | 北京泱深生物信息技术有限公司 | 胆管癌诊治分子标志物及其应用 |
| JP6896650B2 (ja) | 2015-06-17 | 2021-06-30 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法 |
| KR20180021117A (ko) | 2015-06-23 | 2018-02-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 활성 억제를 위한 조성물 및 방법 |
| KR20180015269A (ko) * | 2015-06-24 | 2018-02-12 | 이모듈런 테라퓨틱스 리미티드 | 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| WO2017025496A1 (en) * | 2015-08-12 | 2017-02-16 | Bayer Pharma Aktiengesellschaft | Pharmaceutical combination for the treatment of cancer |
| WO2017037300A1 (en) | 2015-09-04 | 2017-03-09 | Aslan Pharmaceuticals Pte Limited | Varlitinib for use in the treatment of resistant or refractory cancer |
| US20190022092A1 (en) * | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
| WO2017058754A1 (en) * | 2015-09-28 | 2017-04-06 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| EP3355875B1 (en) * | 2015-10-01 | 2021-09-29 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| CN108601767A (zh) | 2015-10-05 | 2018-09-28 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法 |
| CN108136010A (zh) * | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
| WO2017070137A1 (en) * | 2015-10-20 | 2017-04-27 | Bristol-Myers Squibb Company | Combination of ck2 inhibitors and immune checkpoint modulators for cancer treatment |
| WO2017075363A1 (en) * | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| EP3370768B9 (en) * | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| ES2894691T3 (es) * | 2015-11-04 | 2022-02-15 | Astellas Pharma Inc | Composición farmacéutica para propósitos de inmunoterapia y/o inmunoestimulación que contiene compuesto heterocíclico de diamino-carboxamida como principio activo |
| LT3377516T (lt) * | 2015-11-20 | 2022-09-26 | Memorial Sloan Kettering Cancer Center | Kompozicija vėžiui gydyti |
| AU2016366515A1 (en) * | 2015-12-11 | 2018-06-21 | Ruprecht-Karls-Universität Heidelberg | Combined preparations of PKM2 modulators and HMGB1 |
| HUE052893T2 (hu) * | 2016-01-13 | 2021-05-28 | Acerta Pharma Bv | Antifolát és BTK-gátló terápiás kombinációi |
| WO2017129763A1 (en) * | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| WO2017151613A1 (en) | 2016-03-01 | 2017-09-08 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| KR102646979B1 (ko) * | 2016-03-30 | 2024-03-13 | 마이크로바이오 컴퍼니 엘티디. | 면역 체크포인트 조절제 및 공생 미생물군에 의한 발효 산물로의 병용 암 치료법 |
| WO2017201502A1 (en) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| GB201608918D0 (en) * | 2016-05-20 | 2016-07-06 | Aslan Pharmaceuticals Pte Ltd | Method |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| WO2017218970A1 (en) * | 2016-06-17 | 2017-12-21 | Varian Medical Systems, Inc. | Immune modulators in combination with radiation treatment |
| RU2754507C2 (ru) * | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| WO2018013534A1 (en) * | 2016-07-11 | 2018-01-18 | Dana-Farber Cancer Institute, Inc. | Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents |
| WO2018022831A1 (en) * | 2016-07-28 | 2018-02-01 | Musc Foundation For Research Development | Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors |
| CA3029851A1 (en) * | 2016-07-29 | 2018-02-01 | Oncternal Therapeutics, Inc. | Uses of indoline compounds such as tk216 for the treatment of cancer |
| CA3033827A1 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof |
| PT3500299T (pt) * | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| WO2018039441A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| KR20190040302A (ko) | 2016-08-25 | 2019-04-17 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 글루타미나제 억제제와의 병용 요법 |
| CN109689094A (zh) * | 2016-09-06 | 2019-04-26 | 细胞医药股份有限公司 | 免疫刺激剂 |
| JP7200093B2 (ja) | 2016-09-15 | 2023-01-06 | アイデラ・ファーマシューティカルズ，インコーポレーテッド | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| AU2017355512B2 (en) * | 2016-11-04 | 2025-04-03 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
| EP3538111B1 (en) | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| SMT202100573T1 (it) | 2016-12-22 | 2021-11-12 | Calithera Biosciences Inc | Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi |
| GB201701194D0 (en) | 2017-01-24 | 2017-03-08 | Capella Bioscience Ltd | Antigen binding molecules that bind light |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| WO2018209290A1 (en) | 2017-05-12 | 2018-11-15 | Calithera Biosciences, Inc. | Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide |
| CN107099603A (zh) * | 2017-05-31 | 2017-08-29 | 成都克里斯博生物科技有限公司 | 肿瘤免疫t细胞检测试剂盒和检测方法 |
| CA3066053A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| US11839655B2 (en) * | 2017-09-01 | 2023-12-12 | Microvax, Llc | Combination cancer therapy |
| KR20250057947A (ko) | 2017-10-03 | 2025-04-29 | 크리티테크, 인크. | 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| US12458411B2 (en) | 2017-12-07 | 2025-11-04 | Augmedics Ltd. | Spinous process clamp |
| US12521201B2 (en) | 2017-12-07 | 2026-01-13 | Augmedics Ltd. | Spinous process clamp |
| US11312781B2 (en) | 2018-01-24 | 2022-04-26 | Capella Bioscience Ltd. | Antigen binding molecules that bind LIGHT |
| CN108478580A (zh) * | 2018-03-05 | 2018-09-04 | 浙江大学 | 依鲁替尼在制备抗重症肝炎药物中的应用 |
| JP2021523930A (ja) * | 2018-03-23 | 2021-09-09 | アイエスアール イミューン システム レギュレイション ホールディング アクチエボラグ（パブル） | マクロライド化合物と免疫チェックポイント阻害剤との組み合わせ |
| CN108627641A (zh) * | 2018-04-28 | 2018-10-09 | 璞晞（广州）生物免疫技术有限公司 | 肝病t细胞功能的检测评估方法及试剂盒 |
| US11980507B2 (en) | 2018-05-02 | 2024-05-14 | Augmedics Ltd. | Registration of a fiducial marker for an augmented reality system |
| EA202190045A1 (ru) | 2018-06-15 | 2021-03-17 | Янссен Фармацевтика Нв | Составы/композиции, содержащие ибрутиниб |
| ES2984147T3 (es) * | 2018-06-20 | 2024-10-29 | Fujifilm Corp | Medicamento combinado que comprende una composición liposómica de gemcitabina encapsulada y bloqueo de punto de control inmunitario |
| CA3107383A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
| CN110755426B (zh) * | 2018-07-26 | 2022-09-30 | 中国农业大学 | 雷帕霉素及其结构类似物在制备治疗由Msi1基因异位过表达引起疾病的药物中的应用 |
| US12109193B2 (en) * | 2018-07-31 | 2024-10-08 | Loxo Oncology Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
| US11766296B2 (en) | 2018-11-26 | 2023-09-26 | Augmedics Ltd. | Tracking system for image-guided surgery |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11464764B2 (en) | 2018-12-19 | 2022-10-11 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| AU2020212767B2 (en) | 2019-01-25 | 2025-01-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition for treating tumor |
| SG11202108770TA (en) * | 2019-02-15 | 2021-09-29 | Janssen Biotech Inc | Combination therapy for treatment of b-cell malignancies |
| CA3131535A1 (en) * | 2019-04-03 | 2020-10-08 | Targimmune Therapeutics Ag | Immunotherapy for the treatment of cancer |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| BR112021024438A2 (pt) * | 2019-06-03 | 2022-02-15 | Univ Chicago | Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| US12178666B2 (en) | 2019-07-29 | 2024-12-31 | Augmedics Ltd. | Fiducial marker |
| US11980506B2 (en) | 2019-07-29 | 2024-05-14 | Augmedics Ltd. | Fiducial marker |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| US12594271B2 (en) | 2019-11-05 | 2026-04-07 | Health Research, Inc. | Combination therapy for cancer |
| US11382712B2 (en) | 2019-12-22 | 2022-07-12 | Augmedics Ltd. | Mirroring in image guided surgery |
| JP7839962B2 (ja) | 2020-04-15 | 2026-04-03 | ビーワン メディシンズ ワン ゲーエムベーハー | Ｂｃｌ－２阻害剤 |
| WO2021242912A1 (en) | 2020-05-27 | 2021-12-02 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 |
| US11389252B2 (en) | 2020-06-15 | 2022-07-19 | Augmedics Ltd. | Rotating marker for image guided surgery |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| JP2023537338A (ja) * | 2020-07-31 | 2023-08-31 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | がんのための併用療法 |
| US12239385B2 (en) | 2020-09-09 | 2025-03-04 | Augmedics Ltd. | Universal tool adapter |
| US12502163B2 (en) | 2020-09-09 | 2025-12-23 | Augmedics Ltd. | Universal tool adapter for image-guided surgery |
| WO2022056592A1 (en) * | 2020-09-16 | 2022-03-24 | Olivia Newton-John Cancer Research Institute | Treatment and/or prevention of cancers |
| WO2022102715A1 (ja) * | 2020-11-13 | 2022-05-19 | カルナバイオサイエンス株式会社 | 組み合わせ医薬組成物および治療方法 |
| CN112516319A (zh) * | 2020-12-08 | 2021-03-19 | 华中农业大学 | 用于治疗乳腺癌的组合药剂 |
| KR102560178B1 (ko) * | 2021-02-10 | 2023-07-27 | 재단법인 대구경북첨단의료산업진흥재단 | 이미다조[1,5-a]피라진 유도체 화합물 및 이를 유효성분으로 함유하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| CN115068487B (zh) * | 2021-03-11 | 2024-01-30 | 深圳埃格林医药有限公司 | 包含己酸羟孕酮的抗肿瘤联合制剂及其用途 |
| EP4351542A4 (en) * | 2021-06-02 | 2025-04-09 | BeiGene Switzerland GmbH | Method for treating B-cell malignancy with BCL-2 inhibitor |
| US11896445B2 (en) | 2021-07-07 | 2024-02-13 | Augmedics Ltd. | Iliac pin and adapter |
| US12150821B2 (en) | 2021-07-29 | 2024-11-26 | Augmedics Ltd. | Rotating marker and adapter for image-guided surgery |
| EP4387552A4 (en) | 2021-08-18 | 2025-04-30 | Augmedics Ltd. | AUGMENTED REALITY SURGICAL SYSTEM USING DEPTH SENSING |
| CN114634564B (zh) * | 2022-04-18 | 2023-04-04 | 北京华驰千盛生物科技有限公司 | 猫用三联卵黄抗体、制剂及制备方法与用途 |
| EP4511809A4 (en) | 2022-04-21 | 2026-03-11 | Augmedics Ltd | Systems and methods for medical image visualization |
| CN114886901B (zh) * | 2022-05-16 | 2024-03-22 | 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） | 白桦脂酸和rn-18在制备抗猪流行性腹泻病毒药物中的应用 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| CN117122599B (zh) * | 2022-07-01 | 2026-04-21 | 上海交通大学 | 氯法齐明在制备预防和/或治疗猪流行性腹泻病毒感染的药物中的应用 |
| EP4587881A1 (en) | 2022-09-13 | 2025-07-23 | Augmedics Ltd. | Augmented reality eyewear for image-guided medical intervention |
| US12433882B2 (en) | 2022-10-28 | 2025-10-07 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| WO2024123175A1 (en) * | 2022-12-06 | 2024-06-13 | Erasmus University Medical Center Rotterdam | Compositions for treating immune checkpoint blockade therapy resistant cancers |
| WO2024240025A1 (zh) * | 2023-05-22 | 2024-11-28 | 无锡瓴方生物医药科技有限公司 | 一种联合用药物组合物及其应用 |
| CN119529271B (zh) * | 2024-11-25 | 2025-12-05 | 湖北理工学院 | 一种光敏剂载体及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| EP1302468B1 (en) | 1992-12-29 | 2008-12-17 | Abbott Laboratories | Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| CA2252465C (en) | 1996-04-23 | 2007-07-03 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
| RU2192281C2 (ru) | 1996-10-11 | 2002-11-10 | Бристол-Маерс Сквибб Компани | Способы и композиции для иммуномодуляции |
| DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
| CA2367017C (en) | 1999-03-19 | 2009-05-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| PL375144A1 (en) | 2002-07-30 | 2005-11-28 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
| US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US20050250106A1 (en) | 2003-04-24 | 2005-11-10 | David Epstein | Gene knock-down by intracellular expression of aptamers |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2006039644A2 (en) * | 2004-10-01 | 2006-04-13 | Medarex, Inc. | Methods of treating cd30 positive lymphomas |
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| BRPI0622054B8 (pt) * | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| JP5832721B2 (ja) * | 2007-03-14 | 2015-12-16 | バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． | 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物 |
| US20100261776A1 (en) * | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| WO2011133609A2 (en) * | 2010-04-19 | 2011-10-27 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of btk inhibitors |
| JP6457940B2 (ja) | 2012-08-30 | 2019-01-23 | アムジエン・インコーポレーテツド | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 |
| SG11201503459SA (en) * | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
-
2014
- 2014-10-24 JP JP2016550681A patent/JP6508785B2/ja not_active Expired - Fee Related
- 2014-10-24 MX MX2016005283A patent/MX2016005283A/es unknown
- 2014-10-24 WO PCT/US2014/062278 patent/WO2015061752A1/en not_active Ceased
- 2014-10-24 EP EP14855030.4A patent/EP3060251A4/en not_active Withdrawn
- 2014-10-24 AU AU2014339816A patent/AU2014339816B2/en not_active Expired - Fee Related
- 2014-10-24 CN CN201480071331.2A patent/CN105848680A/zh active Pending
- 2014-10-24 TW TW103136913A patent/TWI617309B/zh not_active IP Right Cessation
- 2014-10-24 KR KR1020167013770A patent/KR20160066554A/ko not_active Withdrawn
- 2014-10-24 US US14/523,782 patent/US20150118222A1/en not_active Abandoned
- 2014-10-24 TW TW106113264A patent/TWI660739B/zh not_active IP Right Cessation
- 2014-10-24 BR BR112016009200A patent/BR112016009200A8/pt not_active Application Discontinuation
- 2014-10-24 CA CA2927794A patent/CA2927794A1/en not_active Abandoned
- 2014-10-24 EA EA201690746A patent/EA201690746A1/ru unknown
-
2016
- 2016-04-11 IL IL245042A patent/IL245042A0/en unknown
-
2019
- 2019-03-28 JP JP2019064721A patent/JP2019142890A/ja not_active Ceased
-
2020
- 2020-01-24 US US16/752,231 patent/US20200397895A1/en not_active Abandoned
- 2020-08-27 AU AU2020223721A patent/AU2020223721A1/en not_active Abandoned
- 2020-12-18 JP JP2020210693A patent/JP2021063091A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534157A5 (https=) | ||
| JP7470085B2 (ja) | 抗体およびチェックポイント阻害剤の併用療法 | |
| Kumar et al. | Chemotherapy and targeted therapy in the management of cervical cancer | |
| JP2021524744A5 (https=) | ||
| Vacchelli et al. | Trial watch: Monoclonal antibodies in cancer therapy | |
| JP2017506264A5 (https=) | ||
| Lote et al. | PD-1 and PD-L1 blockade in gastrointestinal malignancies | |
| IL278423B2 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| MX2021002969A (es) | Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1. | |
| JP2018508512A5 (https=) | ||
| Jacome et al. | Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab | |
| JP2017533912A5 (https=) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2018508572A5 (https=) | ||
| PE20180046A1 (es) | Anticuerpos terapeuticos y sus usos | |
| JP2014504294A5 (https=) | ||
| JP2017507990A5 (https=) | ||
| JP2019510733A5 (https=) | ||
| JP2017524715A5 (https=) | ||
| JP2017533266A5 (https=) | ||
| JP2018516911A5 (https=) | ||
| JP2018530554A5 (https=) | ||
| ME02369B (me) | Antitela za terapiju kancera koji eksprimira klaudin 6 | |
| JP2016520082A5 (https=) | ||
| JP2016540042A5 (https=) |